Deep learning–enabled discovery of antibiotics effective against Neisseria gonorrhoeae
Science Translational Medicine 18, eads4699 (2026)
Solving aging: the fundamental question
Welcome
Thank you for visiting my homepage. I am co-founder and CEO of Integrated Bio. Founded in 2022, Integrated Bio is an aging science company developing multimodal biological datasets and AI for drug discovery, focusing on therapeutics for age-related diseases.
Previously, I was a PI supported by an NIH K25 Mentored Quantitative Research Career Development Award at The Broad Institute of MIT and Harvard, where my lab was among the first to apply AI to drug discovery, including the first classes of antibiotics and senolytics.
At Integrated Bio. Photo by Jakub Mosur for The Boston Globe
Selected Work
Cover stories.
Research featured on the covers of scientific journals.
Nature Protocols
An explainable deep learning platform for molecular discovery
Vol. 20, No. 4 · April 2025
Science
Leveraging artificial intelligence in the fight against infectious diseases
Vol. 381, No. 6654 · July 2023
Molecular Systems Biology
Benchmarking AlphaFold-enabled molecular docking predictions for antibiotic discovery
Vol. 18, No. 9 · September 2022
Biophysical Journal
Mechanics and dynamics of bacterial cell lysis
Vol. 116, No. 12 · June 2019
Nature Microbiology
Mechanical strain sensing implicated in cell shape recovery in Escherichia coli
Vol. 2, No. 9 · September 2017
Scroll or drag to browse
Recent
Latest publications.
FATE-MAP predicts teratogenicity and human gastrulation failure modes by integrating deep learning and mechanistic modeling
Nature Communications 17, 3327 (2026)